# Valley Fever Market

> Valley Fever Market Research Report Information, by Types of Treatments (Fluconazole, Itraconazole, Voriconazole, Posaconazole, Others) by Site of Infection (Skin, Liver, Bones, Heart, Brain, Membranes That Surround the Brain and Spinal Cord, Others) - Growth & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 4.37%
- **2024:** $ 1.03 Billion
- **2025:** $ 1.08 Billion
- **2035:** $ 1.65 Billion
- **Key Players:** Astellas Pharma (JP), Gilead Sciences (US), Bristol-Myers Squibb (US), Merck & Co. (US), Pfizer (US), Novartis (CH), Amgen (US), Sanofi (FR), Eli Lilly and Company (US)

**Report ID:** MRFR/Pharma/1339-HCR · **Pages:** 80 · **Author:** Satyendra Maurya & Kinjoll Dey · **Last Updated:** April 06, 2026

**URL:** https://www.marketresearchfuture.com/reports/valley-fever-market-1871

---

## Market Summary

## **Valley Fever Market Overview**

Valley Fever Market Size was valued at USD 0.99 Billion in 2023. The Global Valley Fever  industry is projected to grow from USD 1.03 Billion in 2024 to USD 1.42 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.09% during the forecast period (2024 - 2032).The rising geriatric population who have higher chances of infection is generating a huge demand for treatment drugs for this disease.

Valley fever is a disease caused by the fungus of the genus coccidioides under the family Onagraceae. The disease-causing fungal pathogens live in the soil and people inhaling the fungal spores may get infected. The spores of these fungi get released in the atmosphere even with slight disturbance in soil and conditions like windstorms may cause epidemics in the far-flung areas too. Valley Fever is endemic in some parts of the USA and is also found in South America and Mexico. The initial symptoms of this disease are mild and those are similar to other flues like pneumonia and bronchitis.

However, people with suppressed immune systems are more prone to the disease.

The changing lifestyle and weakening of the human immune system are the major causes for the rising incidence of these diseases. The USA's Center for Disease Control & Prevention has called this disease a silent epidemic as there are no prominent visible systems and therefore the reporting of this disease is very low. It is difficult to prevent the disease as the fungal spores, known as Arthroconidia, are abundantly available in air dust. Antifungal drugs like fluconazole, Amphotericin B, itraconazole, ketoconazole, etc. have been advocated for the treatment of chronic cases.

Moreover, this disease is also reported in cattle and other domestic animals but they are non-zoonotic. The frequent incidences of the disease are pushing medical research organizations to develop specific treatment procedures.

### **Covid 19 Analysis**

Covid-19 pandemic negatively affected the global valley fever market. Covid fear and the high number of covid cases led to the overburdening of the health system which was unable to focus on other milder diseases. Therefore, the reporting of incidents of coccidioidomycosis went low and so did the treatment rate. During the pandemic, the pharmaceutical industry began focusing on covid drugs which affected the production of other drugs including antifungal drugs for the treatment of valley fever. 

## **Valley Fever Market Dynamics**

### **Valley Fever Market Drivers**

The rising incidence of coccidioidomycosis in the elderly population due to declining immune strength and change in lifestyle is driving the growth of the global valley fever market. With improvement in literacy rate, the awareness about this disease has also increased substantially. Therefore, more people are coming out for testing and treatment of the disease. The disease incidence in cattle is also increasing which will contribute to the market growth but at the same time, it is also a cause of concern.

The improvements in public health infrastructure for the treatment of disease are also largely contributing to the strengthening of the market. Moreover, the developments in vaccine technology and pharmaceutical drugs will bring brighter prospects for the valley fever market.

### **Valley Fever Market Restraints**

Though the rising incidence of the disease is contributing to the valley fever market growth, it is also a matter of serious concern. The frequent cases of incidence on cattle may also burden the health system. Moreover, the presence of herbal and home remedies acts as major restraints to valley fever market growth. The poor health infrastructure in many countries and the high price for diagnosis and treatment are other major growth-inhibiting factors.

Valley fever, also known as coccidioidomycosis, is a mammalian fungal disease caused by infection of the fungus coccidioides. Two fungi namely, _Coccidioides immitis_ and _Coccidioides posadasii_, are primarily responsible for the disease. These fungi are soil-borne and readily infect people having weak immune systems. Coccidioidomycosis is endemic in certain parts of the US and is commonly found in some parts of Central and South America.

Valley Fever is a mild disease and more than 60% of the people suffering from this do not show any symptoms while the rest have symptoms similar to [pneumonia](../../../reports/ventilator-associated-pneumonia-vap-market-1377) and bronchitis. The common symptoms are feeling of tiredness, fever, muscle pain, joint pain, fatigue, cough, and also loss of smell and taste. However, Valley Fever is not contagious and only in some cases becomes chronic. This disease can be diagnosed through blood tests and tests of other body fluids. Doctors generally recommend antifungal drugs in case of severe infections but many patients get better with home treatment too.

### **Valley Fever Market Study Objectives**

The specific objectives of this market report on the global Valley fever market are given below:

- To provide a complete overview of the global Valley fever market.
- To analyze and forecast the market in terms of value and volume.
- To visualize the impact of the covid 19 pandemic on the market growth.
- To project the market dynamics including the problems and prospects of the market.
- To provide technical details of products for gaining deep knowledge about the market.
- To provide an overview of the regional market and other market segments.
- To give details about the competitive landscape and key market players.

## **Valley Fever Market Segmentation**

### **Market segmentation, By Types of Treatments**

- Fluconazole
- Itraconazole
- Voriconazole
- Posaconazole
- Others

Fluconazole holds the major market share as it is one of the most effective treatments against valley fever and other similar fungal pathogens. The low price of the drug is also a major contributing factor to its demand and market growth.

### **Market segmentation, By Site of Infection**

- Skin
- Lungs
- Liver
- Bones
- Heart
- Brain
- Membranes that Surround the Brain and Spinal Cord
- Others

Lungs are the most affected organs as this fungus affects the respiratory system the most. However, some of the symptoms like rashes also do occur in the skin.

### **By end-use, the market is divided into**

- Human
- Cattle
- Sheep and goats
- Camel
- Others

Humans are the frequent sufferers of this disease and require more treatment than other mammals. This disease in livestock is very mild and often requires no treatment.

### **Valley Fever Market Regional Analysis**

The different regional markets for the global Valley fever market are:

Among different regions, North America holds the largest Market share as this disease is endemic to this region. The frequent incidence of viral fever leads to the high market demand for the treatment process. According to the Centers for Disease Control & Prevention CDC, the USA alone reported 18,407 cases of coccidioidomycosis in 2019. Moreover, good health infrastructure here is also supporting the market growth.

Latin America follows next to North America in the number of cases. Coccidioidomycosis has been reported sporadically in countries like Mexico, Colombia, Venezuela, Brazil, and Paraguay. The incidence of this disease is also being reported in some Asian countries but it is not prevalent in this region.

## **Valley Fever Market Competitive Landscape**

The major global companies playing a key role in the viral fever market are :

- Novartis
- Anacor Pharmaceuticals
- Johnson and Johnson
- Valeant Pharmaceutical
- Bristol Meyer Squibb
- GlaxoSmithKline Pharmaceuticals Limited
- Galderma S.A.
- Pfizer Inc.

### **Recent Developments**

### **Intended Audience**

This report will be beneficial for every stakeholder of the Valley fever market such as :

- Manufacturers of Valley Fever Drugs
- Antifungal drug manufacturing companies
- Suppliers and Distributors
- Pharmaceutical and Biotechnology companies
- Hospitals and laboratories
- Research institutes
- End users

### **Valley Fever Market Report Overview**

This report from Market Research Future provides an in-depth analysis of the Valley fever market. This report covers both qualitative and quantitative aspects of the market including future projections. Moreover, the technological analysis section of this report gives clear information about the products and processes to help in a better understanding of the market. Furthermore, this report contains a detailed performance-based analysis of all the market segments. This report has also highlighted the key players and the current developments in the Valley fever market. Additionally, Covid-19 analysis has also been added to the report to study the impact of the pandemic on the market.

## Market Drivers

### Increased Research Funding

Increased funding for research into Valley Fever Market is another significant driver for the Valley Fever Market. Government and private organizations are recognizing the need for better understanding and treatment of this disease, leading to enhanced research initiatives. For instance, funding from the National Institutes of Health has been directed towards studying the epidemiology and pathogenesis of Coccidioides. This influx of financial resources is likely to accelerate the development of new diagnostic tools and therapies, thereby expanding the market. As researchers uncover more about the disease, the Valley Fever Market may see a surge in innovative products aimed at prevention and treatment.

### Rising Incidence of Valley Fever

The increasing incidence of Valley Fever Market, primarily caused by the fungus Coccidioides, is a critical driver for the Valley Fever Market. Recent data indicates that the number of reported cases has surged, particularly in endemic regions such as the southwestern United States. This rise in cases is likely attributed to environmental factors, including climate change, which may expand the geographical range of the fungus. As awareness of the disease grows, healthcare providers are more vigilant in diagnosing and reporting cases, further contributing to the market's expansion. The Valley Fever Market is thus positioned to experience growth as healthcare systems adapt to the rising demand for effective diagnostic and therapeutic solutions.

### Advancements in Treatment Options

The Valley Fever Market is witnessing advancements in treatment options, which serve as a crucial driver for market growth. Recent developments in antifungal medications and therapies are providing healthcare professionals with more effective tools to combat Valley Fever Market. For example, the introduction of new azole antifungals has shown promise in treating severe cases of the disease. As treatment options expand, healthcare providers are better equipped to manage the disease, potentially leading to improved patient outcomes. This evolution in treatment modalities is likely to attract investment and interest in the Valley Fever Market, as pharmaceutical companies seek to develop and market innovative solutions.

### Growing Public Health Initiatives

Public health initiatives aimed at raising awareness about Valley Fever Market are becoming increasingly prevalent, serving as a vital driver for the Valley Fever Market. Health departments and organizations are launching campaigns to educate the public about the risks associated with Valley Fever Market, particularly in high-risk areas. These initiatives often include information on prevention strategies and early symptoms, which can lead to earlier diagnosis and treatment. As more individuals become informed about the disease, the demand for diagnostic services and treatment options is likely to increase, thereby propelling the Valley Fever Market forward. The emphasis on public health education may also foster collaboration between various stakeholders, enhancing market growth.

### Increased Collaboration Among Stakeholders

Increased collaboration among various stakeholders, including healthcare providers, researchers, and pharmaceutical companies, is emerging as a significant driver for the Valley Fever Market. Such partnerships are essential for sharing knowledge, resources, and expertise, which can lead to more effective strategies for managing Valley Fever Market. Collaborative efforts may include joint research projects,[clinical trials](https://www.marketresearchfuture.com/reports/clinical-trials-market-7787), and educational programs aimed at improving awareness and treatment of the disease. As stakeholders work together, the Valley Fever Market is likely to benefit from a more coordinated approach to addressing the challenges posed by Valley Fever Market, ultimately enhancing market growth and innovation.

## Future Outlook

The Valley Fever Market is projected to grow at a 4.37% CAGR from 2025 to 2035, driven by increased awareness, improved diagnostics, and rising incidence rates.

**New opportunities:**

- Development of targeted antifungal therapies for resistant strains. Expansion of telemedicine services for remote patient monitoring. Investment in educational campaigns to raise awareness among healthcare providers.

By 2035, the Valley Fever Market is expected to achieve substantial growth, reflecting enhanced treatment options and increased public awareness.

## Segment Insights

### By Types of Treatments: Fluconazole (Largest) vs. Itraconazole (Fastest-Growing)

In the Valley Fever Market, the treatment landscape is primarily dominated by Fluconazole, which holds the largest market share. It has consistently remained the go-to option for patients due to its effectiveness and familiarity among healthcare providers. Following Fluconazole, Itraconazole has emerged as a significant contender, particularly due to its growing adoption in recent years, which reflects the changing preferences in treatment protocols. The growth trends in the Valley Fever Market treatment segment are noteworthy. Factors such as increased awareness of Valley Fever Market and its treatment alternatives have contributed to the rising demand for Itraconazole, marking it as the fastest-growing treatment option. Moreover, ongoing research and clinical developments surrounding these therapies are expected to drive adoption rates further, indicating a shift towards newer and potentially more effective treatment regimens.

Fluconazole (Dominant) vs. Voriconazole (Emerging)

Fluconazole has maintained a dominant position in the Valley Fever Market treatment market primarily due to its extensive clinical usage and established efficacy in combating fungal infections. It is preferred for its broad-spectrum effectiveness, ease of administration, and relatively moderate side effects. On the other hand, Voriconazole is emerging as a notable alternative treatment, gaining traction due to its enhanced anti-fungal potency and improved patient outcomes. It is preferred in complicated cases where Fluconazole may not be effective, thus creating a niche market. Voriconazole's growing acceptance can also be attributed to advancements in treatment protocols and its potential for addressing severe forms of Valley Fever Market, which positions it favourably against the backdrop of market innovation.

### By Site of Infection: Lungs (Largest) vs. Skin (Fastest-Growing)

In the Valley Fever Market, the site of infection segment showcases a diverse distribution of cases. The majority of incidents are recorded in the lungs, which account for the largest share due to the primary nature of coccidioidomycosis as a respiratory disease. Skin infections, while less traditional, have shown a significant rise as awareness increases and diagnosis becomes more widespread, marking them as a noteworthy growing segment among affected populations.

Lungs (Dominant) vs. Skin (Emerging)

The lungs represent the dominant site of infection in the Valley Fever Market, characterized by a higher incidence rate and severe clinical presentations. This site's prominence arises from the fungus's natural route of entry via inhalation, leading to respiratory complications. In contrast, skin infections, although traditionally less recognized, are emerging as a significant concern. Their increase can be attributed to growing awareness and late-stage presentations of the disease, highlighting the need for necessary medical interventions. Both segments require distinct treatment approaches, with lung infections often necessitating rigorous antifungal therapies, while skin infections may demand a combination of topical and systemic treatments.

### By End-Use: Human (Largest) vs. Cattle (Fastest-Growing)

The Valley Fever Market demonstrates a diverse distribution of end-use segments, with the Human segment holding the largest share due to an increasing incidence of the disease in various regions. This segment is driven by rising awareness and improvements in diagnostic methods leading to better detection. The Cattle segment, while comparatively smaller, is witnessing notable growth as farming practices evolve and more emphasis is placed on livestock health, particularly in regions where Valley Fever Market is endemic. Growth trends indicate a bright future for the Cattle segment as climate changes and increasing herd sizes contribute to the spread of diseases like Valley Fever Market. This trend is compounded by the need for effective prevention and treatment strategies in agricultural practices, as livestock health significantly impacts productivity. The human segment remains stable, backed by continuous medical advancements, whereas the cattle segment is poised for significant growth in the coming years.

Human (Dominant) vs. Cattle (Emerging)

In the Valley Fever Market, the Human segment stands out as the dominant end-use category, primarily due to its high prevalence and the critical need for effective diagnosis and treatment. Human health initiatives, coupled with a strong focus on research and development, have solidified this segment's position. Meanwhile, the Cattle segment is emerging as a key player, spurred by heightened awareness of Valley Fever Market's impact on livestock health and productivity. Farmers are increasingly seeking preventative measures and veterinary care to manage this disease, reflecting a shift towards more proactive livestock management strategies. This evolving landscape illustrates the contrast between the established human segment and the rapidly developing cattle sector, underscoring the importance of addressing Valley Fever Market across both ends of the spectrum.

## Regional Market Share Analysis

### North America : Leading Market for Valley Fever

North America is the largest market for Valley Fever, accounting for approximately 65% of the global market share. The region's growth is driven by increasing awareness of the disease, advancements in diagnostic technologies, and supportive regulatory frameworks. The demand for effective antifungal treatments is rising, particularly in endemic areas like Arizona and California, where the incidence of Valley Fever is notably high. Regulatory catalysts, such as expedited approval processes for new therapies, further enhance market growth.

The United States is the leading country in this region, with major pharmaceutical companies like Gilead Sciences, Merck & Co., and Pfizer actively involved in developing treatments. The competitive landscape is characterized by a focus on innovative therapies and collaborations between biotech firms and research institutions. The presence of key players ensures a robust pipeline of products aimed at addressing the unmet medical needs of Valley Fever patients.

### Europe : Emerging Market for Treatments

Europe is emerging as a significant market for Valley Fever, holding approximately 20% of the global market share. The growth is fueled by increasing awareness of the disease, particularly in southern European countries where cases are rising. Regulatory bodies are beginning to recognize the need for effective treatments, leading to a more favorable environment for drug approvals. The demand for antifungal therapies is expected to increase as healthcare providers become more informed about Valley Fever's impact.

Leading countries in this region include Spain and Italy, where the incidence of Valley Fever is becoming more prevalent. The competitive landscape features both established pharmaceutical companies and new entrants focusing on innovative treatment options. Key players like Novartis and Sanofi are investing in research and development to address the growing need for effective therapies in the region.

### Asia-Pacific : Growing Awareness and Demand

The Asia-Pacific region is witnessing a gradual increase in awareness and demand for Valley Fever treatments, holding about 10% of the global market share. The growth is driven by rising healthcare expenditures and an increasing focus on infectious diseases. Countries like Australia and India are beginning to recognize the importance of addressing Valley Fever, leading to a more proactive approach in healthcare policies. Regulatory frameworks are evolving to support the introduction of new therapies, enhancing market potential.

Australia is currently the leading country in this region, with a growing number of healthcare providers focusing on Valley Fever diagnosis and treatment. The competitive landscape is characterized by collaborations between local biotech firms and international pharmaceutical companies. Key players such as Astellas Pharma and Amgen are exploring opportunities to expand their presence in this emerging market.

### Middle East and Africa : Untapped Potential in Treatments

The Middle East and Africa region represents an untapped market for Valley Fever, accounting for approximately 5% of the global market share. The growth potential is significant, driven by increasing awareness of fungal infections and the need for effective treatments. Countries in this region are beginning to recognize the importance of addressing Valley Fever, particularly in areas with favorable climates for the disease. Regulatory bodies are starting to implement guidelines to facilitate the approval of new therapies, which could enhance market growth.

South Africa and Kenya are among the leading countries in this region, where healthcare systems are gradually improving. The competitive landscape is still developing, with a mix of local and international players entering the market. Companies like Eli Lilly and Company are exploring opportunities to introduce innovative treatments, aiming to meet the growing demand for effective Valley Fever therapies.

## Competitive Benchmarking

The Valley Fever Market is characterized by a complex interplay of competitive dynamics, driven by increasing awareness of the disease and advancements in treatment options. Key players such as Gilead Sciences (US), Merck & Co. (US), and Astellas Pharma (JP) are strategically positioned to leverage their extensive research capabilities and established market presence. Gilead Sciences (US) focuses on innovative therapies, particularly in antifungal treatments, while Merck & Co. (US) emphasizes partnerships to enhance its product pipeline. Astellas Pharma (JP) is investing in regional expansion, particularly in areas with high incidence rates, thereby shaping a competitive environment that is increasingly focused on specialized treatment solutions.

In terms of business tactics, companies are localizing manufacturing and optimizing supply chains to enhance efficiency and responsiveness to market demands. The Valley Fever Market appears moderately fragmented, with a mix of established pharmaceutical giants and emerging biotech firms. The collective influence of these key players fosters a competitive structure that encourages innovation and collaboration, as companies seek to differentiate themselves through unique therapeutic offerings and improved patient outcomes.

In August 2025, Gilead Sciences (US) announced a strategic partnership with a leading biotech firm to co-develop a novel antifungal agent specifically targeting Valley Fever. This collaboration is significant as it not only expands Gilead's portfolio but also enhances its research capabilities in addressing unmet medical needs in this area. The partnership is expected to accelerate the development timeline and improve access to innovative treatments for patients.

In September 2025, Merck & Co. (US) launched a new initiative aimed at increasing awareness and education about Valley Fever among healthcare providers and patients. This initiative underscores Merck's commitment to addressing the disease's public health impact and reflects a broader trend among pharmaceutical companies to engage in community outreach. By fostering education, Merck aims to improve early diagnosis and treatment, which could lead to better patient outcomes and increased market share.

In July 2025, Astellas Pharma (JP) expanded its operations in the southwestern United States, where Valley Fever is endemic. This expansion includes the establishment of a new manufacturing facility dedicated to producing antifungal therapies. The strategic importance of this move lies in Astellas' ability to enhance its supply chain efficiency and reduce lead times for product availability, thereby positioning itself as a key player in the regional market.

As of October 2025, current competitive trends in the Valley Fever Market are increasingly defined by digitalization, sustainability, and the integration of artificial intelligence in drug development. Strategic alliances are becoming more prevalent, as companies recognize the value of collaboration in navigating complex regulatory environments and accelerating innovation. Looking ahead, competitive differentiation is likely to evolve from traditional price-based competition to a focus on technological advancements, innovative treatment modalities, and robust supply chain reliability, ultimately enhancing patient care and outcomes.

## Recent News & Developments

- In December 2019, UC Berkeley School of Public Health, A premier health Research Institute in California, announced the launch of new major research initiatives to tackle valley fever. A 5-year grant of 3.8 million USD is being provided by the [National Institute of Health (NIH)](https://www.nih.gov/) for conducting the research.

### **Intended Audience**

This report will be beneficial for every stakeholder of the Valley fever market such as :

- Manufacturers of Valley Fever Market Drugs
- Antifungal drug manufacturing companies
- Suppliers and Distributors
- Pharmaceutical and Biotechnology companies
- Hospitals and laboratories
- Research institutes
- End users

## Report Scope

| MARKET SIZE 2024 | 1.03(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 1.075(USD Billion) |
| MARKET SIZE 2035 | 1.649(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 4.37% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Astellas Pharma (JP), Gilead Sciences (US), Bristol-Myers Squibb (US), Merck & Co. (US), Pfizer (US), Novartis (CH), Amgen (US), Sanofi (FR), Eli Lilly and Company (US) |
| Segments Covered | Types of Treatments, Site of Infection |
| Key Market Opportunities | Advancements in diagnostic technologies enhance early detection and treatment options in the Valley Fever Market. |
| Key Market Dynamics | Rising awareness and diagnosis of Valley Fever drive demand for innovative treatment options and improved patient care. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Valley Fever Market as of 2024?**
A: The Valley Fever Market was valued at 1.03 USD Billion in 2024.

**Q: What is the projected market valuation for the Valley Fever Market in 2035?**
A: The market is projected to reach 1.649 USD Billion by 2035.

**Q: What is the expected CAGR for the Valley Fever Market during the forecast period 2025 - 2035?**
A: The expected CAGR for the Valley Fever Market during 2025 - 2035 is 4.37%.

**Q: Which companies are considered key players in the Valley Fever Market?**
A: Key players in the Valley Fever Market include Astellas Pharma, Gilead Sciences, Bristol-Myers Squibb, Merck & Co., Pfizer, Novartis, Amgen, Sanofi, and Eli Lilly and Company.

**Q: What are the main treatment types contributing to the Valley Fever Market?**
A: The main treatment types include Fluconazole, Itraconazole, Voriconazole, Posaconazole, and others.

**Q: How much revenue did Fluconazole generate in the Valley Fever Market in 2024?**
A: Fluconazole generated approximately 0.4 USD Billion in 2024, with projections indicating growth to 0.63 USD Billion.

**Q: What segment accounted for the highest revenue in the Valley Fever Market by site of infection?**
A: The lungs segment accounted for the highest revenue, generating 0.45 USD Billion in 2024 and projected to reach 0.7 USD Billion.

**Q: What is the revenue projection for the human end-use segment in the Valley Fever Market by 2035?**
A: The human end-use segment is projected to generate approximately 0.65 USD Billion by 2035.

**Q: Which treatment type is expected to see the most growth in the Valley Fever Market?**
A: Fluconazole appears to be on track for the most growth, with projections indicating an increase from 0.4 USD Billion to 0.63 USD Billion.

**Q: What is the revenue range for the liver infection segment in the Valley Fever Market?**
A: The liver infection segment generated 0.1 USD Billion in 2024 and is projected to grow to 0.15 USD Billion by 2035.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/valley-fever-market-1871*